Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer Biotech Investing
Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine Pharmaceutical Investing
RINVOQ Achieved Superiority Versus DUPIXENT® For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis Biotech Investing
Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics Psychedelics Investing
Hollister Biosciences 100% Owned Subsidiary Venom Extracts Achieves Final $40 Million Revenue Milestone Psychedelics Investing
Gilead Announces Racial Equity Community Impact Fund to Support Black Communities Across United States Biotech Investing
